XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended
Apr. 18, 2022
Apr. 30, 2022
Mar. 31, 2018
Mar. 31, 2023
Dec. 31, 2022
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Acquisitions                
Goodwill       $ 3,301,959 $ 3,301,959      
Pelican Therapeutics, Inc.                
Acquisitions                
Ownership interest in subsidiary       85.00% 85.00% 85.00% 80.00%  
Pelican Therapeutics, Inc.                
Acquisitions                
Percentage of voting interests acquired in acquisition               80.00%
Cash consideration     $ 200,000          
Milestone payment         $ 0      
Pelican Therapeutics, Inc. | Stockholders                
Acquisitions                
Cash consideration     $ 300,000          
Elusys Therapeutics                
Acquisitions                
Earn out payments period 12 years              
Percentage of earn out payments 10.00%              
Frequency of periodic earn out payment 1 year              
Period of occurrence of earn payment 9 years              
Receivable consideration $ 22,318,685              
Consideration paid   $ 20,800,000            
Holding back related to future fulfillment cost   $ 1,500,000            
Contract receivables 24,526,232              
Fair value of the purchase consideration 42,900,000              
Cash consideration 3,000,000              
Deferred cash consideration 2,000,000              
Fair value of contingent and deferred consideration liabilities $ 37,900,000              
Discount rate for deferred consideration 24.00%              
Discount rate for earn out liabilities 14.00%              
Preliminary value of Additional Earn Out liability as percentage 80.00%              
Goodwill $ 3,301,960              
Goodwill deductible for tax purposes 15 years